China NT Pharma Group Co (HKSE:01011) EBITDA Margin % : 21.70% (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is China NT Pharma Group Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. China NT Pharma Group Co's EBITDA for the six months ended in Jun. 2024 was HK$7.31 Mil. China NT Pharma Group Co's Revenue for the six months ended in Jun. 2024 was HK$33.69 Mil. Therefore, China NT Pharma Group Co's EBITDA margin for the quarter that ended in Jun. 2024 was 21.70%.

China NT Pharma Group Co EBITDA Margin % Historical Data

The historical data trend for China NT Pharma Group Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China NT Pharma Group Co EBITDA Margin % Chart

China NT Pharma Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBITDA Margin %

Get a 7-Day Free Trial

-40.94

-7.84

18.06

-56.05

China NT Pharma Group Co Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EBITDA Margin %	Get a 7-Day Free Trial															15.15	112.61	-	21.70	-431.12

Competitive Comparison of China NT Pharma Group Co's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China NT Pharma Group Co's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where China NT Pharma Group Co's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

China NT Pharma Group Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

China NT Pharma Group Co's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	1.455	/	8.057
	=	18.06 %

China NT Pharma Group Co's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	7.31	/	33.693
	=	21.70 %

China NT Pharma Group Co (HKSE:01011) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

China NT Pharma Group Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of China NT Pharma Group Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

China NT Pharma Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China NT Pharma Group Co Ltd (HKSE:01011) » Definitions » EBITDA Margin %

Traded in Other Exchanges

N/A

Address

198 Wellington Street, 28th Floor, The Wellington, Sheung Wan, Hong Kong, HKG

Website

http://www.ntpharma.com

China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The company operates in a single segment of Proprietary product production and sales. The company earns the majority of its revenue from the domestic market. The Group's revenue from an external customer was derived solely from its operations in the PRC.

Executives

Ieong Chong Mang
Golden Base Investment Limited
Wang Minzhi	2101 Beneficial owner
Shum Ning
Chin Yu
Ng Tit
Ieong Iat	2101 Beneficial owner

China NT Pharma Group Co Headlines

No Headlines